Fewer biopsy cores may be safer and just as accurate for prostate cancer detection
NCT ID NCT04183699
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked at whether taking fewer systematic biopsy cores (6 instead of 20) during an MRI-targeted prostate biopsy could still detect dangerous prostate cancers while reducing risks like infection and overdiagnosis. The trial involved 126 men with suspicious MRI results. It was terminated early, so the findings are limited.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could help doctors use fewer biopsy cores during MRI-targeted prostate biopsies, reducing infection risk and overdiagnosis while still catching dangerous cancers.
- What could go wrong
- The trial was terminated early, so results may be incomplete. The approach may not work for all patients or may miss some cancers.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
IRCCS San Raffaele
Milan, 20132, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new tracer light up hidden prostate cancer?
- Could deep breaths before surgery ward off Post-Op confusion?
- A second look: MRI screening may spot hidden prostate cancers
- Can precision protons spare the bowel in prostate cancer?
- AI coaches doctors on cancer risk talks
- Can an immune booster make hormone therapy work better against prostate cancer?